Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Dr. Reddy's Laboratories Ltd.
- 2,589.90 INR
- -2.05
- -0.08%
India
Jan 15, 2019Ticker
BOM(500124)Prev. close
2,591.95Market cap (INR)
430,265.93MMarket cap (USD)
6,058.80MShares
166.00M
In the news
- Dr. Reddy's wins US court respite for generic Suboxone sale Nov 21, 2018
- Cipla warns of 'multiple headwinds' after quarterly profit unexpectedly falls Nov 5, 2018
- Dr. Reddy's quarterly profit exceeds estimates on India, emerging market sales Oct 26, 2018
- Sun Pharmaceutical profit beats estimates, helped by tax gain May 25, 2018
- Dr. Reddy's Laboratories posts surprise fall in profit amid US pricing pressure May 22, 2018 See more articles on Dr. Reddy's Laboratories Ltd.
Business Summary
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Financial Highlights
| Mar 2018 | INR | USD |
| Revenue | 142,028M | 2,203.14M |
| Gross Profit | 71,189M | 1,104.28M |
| Operating income | 11,182M | 173.45M |
| Income before tax | 13,997M | 217.12M |
| Net income | 9,806M | 152.11M |
| EBITDA | 22,892M | 355.10M |
| Diluted EPS | 59.01 | 0.91 |
| Dividends Per Share | 20 | 0.31 |
| Total Assets | 225,604M | 3,459.03M |
| Total liabilities | 99,144M | 1,520.10M |
| Total equity | 126,460M | 1,938.92M |
| Operating cash flow | 17,110M | 265.41M |
| Currency in INR | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 132,170M | 148,189M | 154,708M | 140,809M | 142,028M |
| Gross Profit | 72,466M | 81,457M | 87,272M | 73,531M | 71,189M |
| Operating income | 24,119M | 25,878M | 28,806M | 12,878M | 11,182M |
| Income before tax | 26,432M | 27,968M | 26,911M | 14,304M | 13,997M |
| Net income | 21,515M | 22,179M | 20,013M | 12,039M | 9,806M |
| EBITDA | 31,225M | 33,978M | 39,056M | 24,155M | 22,892M |
| Diluted EPS | 126.04 | 129.75 | 116.99 | 72.09 | 59.01 |
| Dividends Per Share | 18 | 20 | 20 | 20 | 20 |
| Total Assets | 170,223M | 194,762M | 207,650M | 219,821M | 225,604M |
| Total liabilities | 79,422M | 83,460M | 79,314M | 95,777M | 99,144M |
| Total equity | 90,801M | 111,302M | 128,336M | 124,044M | 126,460M |
| Operating cash flow | 19,280M | 24,760M | 41,613M | 21,216M | 17,110M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 2,187.00M | 2,423.62M | 2,363.00M | 2,099.83M | 2,203.14M |
| Gross Profit | 1,199.08M | 1,332.22M | 1,332.99M | 1,096.54M | 1,104.28M |
| Operating income | 399.09M | 423.23M | 439.98M | 192.04M | 173.45M |
| Income before tax | 437.36M | 457.41M | 411.03M | 213.31M | 217.12M |
| Net income | 356.00M | 362.73M | 305.67M | 179.53M | 152.11M |
| EBITDA | 516.67M | 555.70M | 596.54M | 360.21M | 355.10M |
| Diluted EPS | 2.08 | 2.12 | 1.78 | 1.07 | 0.91 |
| Dividends Per Share | 0.29 | 0.32 | 0.30 | 0.29 | 0.31 |
| Total Assets | 2,850.23M | 3,112.14M | 3,135.64M | 3,385.24M | 3,459.03M |
| Total liabilities | 1,329.85M | 1,333.62M | 1,197.68M | 1,474.96M | 1,520.10M |
| Total equity | 1,520.38M | 1,778.51M | 1,937.95M | 1,910.27M | 1,938.92M |
| Operating cash flow | 319.02M | 404.94M | 635.59M | 316.38M | 265.41M |
Valuation Measures
| Mar 2018 | |
| PER | 35.21 |
| ROA | 4.40% |
| ROE | 7.82% |
| Operating margin | 7.87% |
| Profit margin | 6.90% |
Key executives
- Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
- President, CFO & Global Head-IT: Saumen Chakraborty
- Chief Operating Officer & Global Head-Generics: Erez Israeli
- Secretary & Compliance Officer: Sandeep Poddar
- Executive Vice President & Head-Biologics: Cartikeya Reddy
Shareholders
- Dr. Reddy's Holdings Ltd. (24.8%)
- First State Investment Management (UK) Ltd. (6.7%)
- Life Insurance Corp. of India (4.4%)
- OppenheimerFunds, Inc. (3.8%)
- Aditya Birla Sun Life AMC Ltd. (2.2%)
- BlackRock Fund Advisors (2.0%)
- Franklin Templeton Asset Management (India) Pvt Ltd. (1.7%)
- Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (1.5%)
- SBI Funds Management Pvt Ltd. (1.3%)
- TELUK KEMANG INVESTMENTS MAURITIUS LTD (1.2%)
Contact Details
- Website:http://www.drreddys.com
- Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
- Phone: +91.40.49002900
Related Companies
- Dr. Reddy's Laboratories Ltd. /API Manufacturing Bus/
- Dr. Reddy's New Zealand Ltd.
- Imperial Credit Pvt Ltd.
- Ducere Pharma LLC/Otc Bus/
- UCB SA /Established Product Bus/
- Dr. Reddy's Laboratories SA
- Dr. Reddy's Laboratories Ltd. (Russia)
- Zenovus Biotech Pvt Ltd.
- Reddy Holding GmbH
- Dr. Reddy's Pharma SEZ Ltd.
- Dr. Reddy's Bio-Sciences Ltd.
- Promius Pharma LLC
- Industrias Quimicas Falcon de Mexico SA de CV
- Dr. Reddy's Laboratories (UK) Ltd.
- Kunshan Rotam Reddy Pharmaceutical Co. Ltd.
- Perlecan Pharma Pvt Ltd.
- Macred India Pvt Ltd.
- BASF SE /Pharmaceutical Contract Manufacturing Unit/
- Reddy Pharma Italia SpA
- Dowpharma /Small Molecules Business/
- Dr. Reddy's Laboratories, Inc.
- Laboratorios Litaphar SA
- F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
- Trigenesis Therapeutics, Inc.
- betapharm Arzneimittel GmbH
- OctoPlus N.V.
- Dr. Reddy's Laboratories (EU) Ltd
Competitors
- Novartis AG
- Perrigo Co. Plc
- Sun Pharmaceutical Industries Limited
- Mylan N.V.
- Pfizer Inc.
- KRKA dd
- Sanofi
- Lupin Limited
- Cipla Limited
- Teva Pharmaceutical Industries Limited
- GlaxoSmithKline Pharmaceuticals Limited
- Pfizer Limited
- Chemical Works of Gedeon Richter Plc
- Bayer AG
- Takeda Pharmaceutical Co. Ltd.
- STADA Arzneimittel AG
- Endo International Plc
- Alkem Laboratories Ltd.
- Cadila Healthcare Limited
- Sanofi India Limited
- Abbott India Limited
- Piramal Enterprises Ltd.
- Fresenius SE & Co. KGaA
- Aurobindo Pharma Ltd
- Catalent Inc
- Dishman Carbogen Amcis Ltd.
- GlaxoSmithkline Consumer Healthcare Ltd
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Cambrex Corporation
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 15 Jan, 2019Your full access to the Nikkei Asian Review has expired
